Rubicon Founders LLC Makes New Investment in Privia Health Group, Inc. $PRVA

Rubicon Founders LLC bought a new position in Privia Health Group, Inc. (NASDAQ:PRVA) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 5,971,079 shares of the company’s stock, valued at approximately $153,635,863,000. Privia Health Group accounts for approximately 78.2% of Rubicon Founders LLC’s investment portfolio, making the stock its largest holding. Rubicon Founders LLC owned 4.67% of Privia Health Group as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. GAMMA Investing LLC raised its stake in Privia Health Group by 14.0% in the second quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock worth $124,000 after buying an additional 592 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Privia Health Group by 8.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock valued at $213,000 after acquiring an additional 840 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock worth $535,000 after acquiring an additional 898 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock worth $385,000 after acquiring an additional 903 shares during the period. Finally, Hantz Financial Services Inc. raised its position in shares of Privia Health Group by 456.2% in the 4th quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after acquiring an additional 926 shares in the last quarter. Institutional investors own 94.48% of the company’s stock.

Insider Buying and Selling at Privia Health Group

In related news, CFO David Mountcastle sold 24,734 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total transaction of $680,185.00. Following the sale, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This represents a 11.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Shawn Morris sold 88,110 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the sale, the director directly owned 76,651 shares in the company, valued at $1,941,569.83. This trade represents a 53.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 327,886 shares of company stock valued at $8,628,256 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Privia Health Group Stock Down 0.5%

Privia Health Group stock opened at $21.02 on Tuesday. The company has a market capitalization of $2.68 billion, a P/E ratio of 100.10, a PEG ratio of 1.67 and a beta of 0.85. The stock’s 50 day moving average is $24.54 and its 200 day moving average is $23.22. Privia Health Group, Inc. has a twelve month low of $19.53 and a twelve month high of $28.82.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%.The company had revenue of $632.63 million during the quarter, compared to analyst estimates of $597.33 million. During the same quarter last year, the company earned $0.24 EPS. The firm’s revenue for the quarter was up 21.4% on a year-over-year basis. As a group, equities analysts expect that Privia Health Group, Inc. will post 0.27 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PRVA shares. Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Canaccord Genuity Group set a $32.00 price objective on Privia Health Group in a research report on Friday, August 7th. Barclays dropped their target price on shares of Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Finally, Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.00.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.